Amgen announced new findings from its VESALIUS-CV trial showing Repatha reduced the risk of death by 20% in high-risk heart patients. This positive clinical trial data could significantly expand Repatha's market and reinforce its position as a leading cardiovascular treatment.
Amgen reported that its drug Repatha significantly reduced the risk of death by 20% in high-risk heart patients without a prior heart attack or stroke. This is a major positive development as it expands the drug's proven benefits beyond just preventing cardiovascular events to directly reducing mortality. This could lead to increased prescriptions and market share for Repatha, boosting Amgen's revenue and profitability in the long term. For traders, this presents a clear opportunity for Amgen stock due to the enhanced commercial prospects of a key product.